vimarsana.com
Home
Live Updates
First-in-Class Investigational SX-682 Demonstrates Single-Ag
First-in-Class Investigational SX-682 Demonstrates Single-Ag
First-in-Class Investigational SX-682 Demonstrates Single-Agent Efficacy in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes
/PRNewswire/ -- Syntrix Pharmaceuticals today announced results from a single-arm, open-label Phase 1 trial of single-agent SX-682, an investigational CXCR1/2...
Related Keywords
United States ,
Americans ,
American ,
David Sallman ,
Aaron Schuler ,
John Zebala ,
H Lee Moffitt Cancer Center ,
Syntrix Pharmaceuticals ,
American Society Of Hematology ,
Research Institute ,
International Prognostic Scoring System ,
National Heart ,
Blood Institute ,
Prnewswire Syntrix Pharmaceuticals ,
Oral Session ,
Meeting Support ,
Promising Target ,
Patients Treated ,
Recommended Phase ,
Objective Response ,
Hematologic Improvement ,
Moffitt Cancer Center ,
American Society ,
Annual Meeting ,
Myelodysplastic Syndromes ,
Health Care Amp Hospitals ,
Medical Pharmaceuticals ,
Pharmaceuticals ,
Clinical Trials Amp Medical Discoveries ,
Trade Show News ,